Nyxoah (NYXH) Expected to Announce Earnings on Tuesday

Key Points

• Nyxoah (NASDAQ: NYXH) is expected to announce its Q2 2025 earnings on August 5th, with analysts projecting a loss of ($0.60) per share and revenue of $1.33 million.
• In its last earnings report, Nyxoah missed estimates with a loss of ($0.63) per share and revenue of $1.12 million, falling short of the expected $1.64 million.
• Recent analyst activities include Stifel Nicolaus cutting their price target from $15.00 to $14.00 while maintaining a "buy" rating on the stock.

Nyxoah (NASDAQ:NYXH - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect Nyxoah to post earnings of ($0.60) per share and revenue of $1.33 million for the quarter.

Nyxoah (NASDAQ:NYXH - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.14). Nyxoah had a negative return on equity of 63.37% and a negative net margin of 1,571.39%. The firm had revenue of $1.12 million for the quarter, compared to analysts' expectations of $1.64 million. On average, analysts expect Nyxoah to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Nyxoah Stock Down 4.8%

Shares of NYXH stock traded down $0.36 on Wednesday, reaching $7.12. 37,825 shares of the company's stock traded hands, compared to its average volume of 38,204. The company has a market capitalization of $242.51 million, a P/E ratio of -3.34 and a beta of 1.62. Nyxoah has a 12-month low of $5.55 and a 12-month high of $11.87. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.35 and a current ratio of 3.59. The business's 50 day moving average price is $7.74 and its two-hundred day moving average price is $8.32.

Analyst Ratings Changes

NYXH has been the subject of a number of analyst reports. Stifel Nicolaus reduced their price target on Nyxoah from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Monday, April 21st. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price objective on shares of Nyxoah in a report on Tuesday, April 8th.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.